Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

344 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radio-sensitizing effect of MEK inhibition in glioblastoma in vitro and in vivo.
Houweling M, Abdul UK, Brahm C, Lagerweij T, Heukelom S, Koken PW, Honeywell R, Wedekind LE, Peters GJ, Verheul H, Sminia P, Noske D, Wurdinger T, Westerman BA. Houweling M, et al. J Cancer Res Clin Oncol. 2023 Jan;149(1):297-305. doi: 10.1007/s00432-022-04483-3. Epub 2022 Dec 1. J Cancer Res Clin Oncol. 2023. PMID: 36451044
Safety, Efficacy, and Biomarker Analysis of Crizotinib in MET-Mutated Non-Small Cell Lung Cancer-Results from the Drug Rediscovery Protocol.
Verkerk K, van der Wel TJWT, Zeverijn LJ, Geurts BS, Spiekman IAC, de Wit GF, Roepman P, Jansen AML, van der Noort V, Smit EF, Hoeben A, Hendriks LEL, van den Heuvel MM, Piet B, Herder GJM, Hashemi SMS, Gelderblom H, Verheul HMW, Voest EE, de Langen AJ. Verkerk K, et al. Among authors: verheul hmw. Clin Cancer Res. 2024 Dec 2;30(23):5323-5332. doi: 10.1158/1078-0432.CCR-24-1925. Clin Cancer Res. 2024. PMID: 39352721 Clinical Trial.
The STELLAR trial: a phase II/III randomized trial of high-dose, intermittent sunitinib in patients with recurrent glioblastoma.
Janssen JBE, Brahm CG, Driessen CML, Nuver J, Labots M, Kouwenhoven MCM, Sanchez Aliaga E, Enting RH, de Groot JC, Walenkamp AME, van Linde ME, Verheul HMW. Janssen JBE, et al. Among authors: verheul hmw. Brain Commun. 2024 Jul 30;6(4):fcae241. doi: 10.1093/braincomms/fcae241. eCollection 2024. Brain Commun. 2024. PMID: 39114330 Free PMC article. Clinical Trial.
The Innate Immune Landscape of dMMR/MSI Cancers Predicts the Outcome of Nivolumab Treatment: Results from the Drug Rediscovery Protocol.
Zeverijn LJ, Geurts BS, Battaglia TW, van Berge Henegouwen JM, de Wit GF, Hoes LR, van der Wijngaart H, van der Noort V, Roepman P, de Leng WWJ, Jansen AML, Chalabi M, van Herpen CML, Devriese LA, Erdkamp FLG, Labots M, de Jonge MJA, Kerver ED, Bins AD, Leek LVM, Notohardjo JCL, van den Eertwegh AJM, Wessels LFA, Verheul HMW, Gelderblom H, van de Haar J, Voest EE. Zeverijn LJ, et al. Among authors: verheul hmw. Clin Cancer Res. 2024 Oct 1;30(19):4339-4351. doi: 10.1158/1078-0432.CCR-24-0480. Clin Cancer Res. 2024. PMID: 39024037
Maximizing Treatment Opportunities: Assessing Protocol Waivers' Impact on Safety and Outcome in the Drug Rediscovery Protocol.
van Berge Henegouwen JM, Zeverijn LJ, Geurts BS, Hoes LR, van der Wijngaart H, van der Noort V, Huitema ADR, de Vos FYF, Grünberg K, Bloemendal HJ, Verheul HMW, Voest EE, Gelderblom H. van Berge Henegouwen JM, et al. Among authors: verheul hmw. Clin Cancer Res. 2024 Sep 3;30(17):3937-3943. doi: 10.1158/1078-0432.CCR-23-3917. Clin Cancer Res. 2024. PMID: 38926908
Exploring immune status in peripheral blood and tumor tissue in association with survival in patients with multi-organ metastatic colorectal cancer.
Bakkerus L, Subtil B, Bontkes HJ, Gootjes EC, Reijm M, Vullings M, Verrijp K, Bokhorst JM, Woortman C, Nagtegaal ID, Jonker MA, van der Vliet HJ, Verhoef C, Gorris MAJ, de Vries IJM, de Gruijl TD, Verheul HMW, Buffart TE, Tauriello DVF. Bakkerus L, et al. Among authors: verheul hmw. Oncoimmunology. 2024 Jun 10;13(1):2361971. doi: 10.1080/2162402X.2024.2361971. eCollection 2024. Oncoimmunology. 2024. PMID: 38868078 Free PMC article.
344 results